Rx Licensing Deals: New Feature May Be Payments Tied To Patent Defense
Executive Summary
Pharmaceutical companies are looking at ways to design licensing agreements to tie payments to the ability to defend product exclusivity, Lilly Assistant General Counsel Steven Caltrider told the recent Biotechnology Industry Organization CEO & Investor conference in New York City